ArticleMolecular biomedicine2025
Peripheral TERT- positive leukocytes as a biomarker of the local and systemic immune failure in early-stage lung adenocarcinoma progression.
Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding early lung adenocarcinoma progression by single-cell and spatial transcriptomics reveals a CMA-related prognostic signature.Frontiers in immunology · 2026Article
- Preoperative evaluation of solitary pulmonary nodules and adenocarcinoma invasiveness using ultra-high-resolution computed tomography and multidimensional liquid biopsy: a prospective exploratory study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The prognosis of early-stage lung adenocarcinoma (LUAD) worsens significantly during the progression from adenocarcinoma in situ/minimally invasive adenocarcinoma (AIS/MIA) to invasive adenocarcinoma (IAC), emphasizing the importance of understanding the molecular mechanisms underlying this transition for effective clinical intervention. This study analyzed data from 990 eligible early-stage LUAD patients meeting the following inclusion criteria: written informed consent, absence of neoadjuvant therapy, planned surgical resection, postoperative pathological confirmation of LUAD, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Analysis of a retrospective cohort of 601 stage I LUAD patients demonstrated a significant correlation between the extent of tumor invasion and 5-year survival rates. Transcriptomic profiling revealed a progressively immunosuppressive tumor microenvironment (TME) during the AIS/MIA-to-IAC transition, characterized by dysfunctional immune cells and diminished local anti-tumor immunity. Notably, peripheral blood analysis from 389 patients showed a significant decrease in telomerase reverse transcriptase-positive (TERT +) leukocytes with tumor progression, a change detectable earlier than circulating tumor cells (CTCs). Two-year follow-up data corroborated these findings. This study elucidates key biological events in early-stage LUAD progression, revealing that the tumor remodels both local and systemic immunity to facilitate its advancement. The reduction in peripheral TERT + leukocytes emerges as a potential non-invasive biomarker for the early detection of malignant progression, supporting the rationale for immune-based interventions at earlier disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.